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Abstract
Background: New patient-centric integrated care models are enabled by the capability to exchange the patient’s data
amongst stakeholders, who each specialise in different aspects of the patient’s care. This requires a robust, trusted and
flexible mechanism for patients to offer consent to share their data. Furthermore, new IT technologies make it easier to give
patients more control over their data, including the right to revoke consent. These characteristics challenge the traditional
paper-based, single-organisation-led consent process. The Dovetail digital consent application uses a mobile application
and blockchain based infrastructure to offer this capability, as part of a pilot allowing patients to have their data shared
amongst digital tools, empowering patients to manage their condition within an integrated care setting.
Objective: To evaluate patient perceptions towards existing consent processes, and the Dovetail blockchain based digital
consent application as a means to manage data sharing in the context of diabetes care.
Method: Patients with diabetes at a General Practitioner practice were recruited. Data were collected using focus groups
and questionnaires. Thematic analysis of the focus group transcripts and descriptive statistics of the questionnaires was
performed.
Results: There was a lack of understanding of existing consent processes in place, and many patients did not have any
recollection of having previously given consent. The digital consent application received favourable feedback, with patients
recognising the value of the capability offered by the application. Patients overwhelmingly favoured the digital consent
application over existing practice.
Conclusions: Digital consent was received favourably, with patients recognising that it addresses the main limitations of the
current process. Feedback on potential improvements was received. Future work includes confirmation of results in a
broader demographic sample and across multiple conditions.
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Introduction
Background
Integrated care is often synonymous with coordinated
and seamless care, usually describing a multi-
disciplinary service structured around the patient, and
integrated at multiple levels such as organisation, func-
tional, service and clinical.1 A number of healthcare
services are offering new digital technologies to patients
(e.g. mobile applications and integration of health sys-
tems), which contribute to the transformation of ser-
vice towards achieving the goals of integrated care.2
Examples of such services provide a number of advan-
tages, such as on-demand personalised advice and edu-
cation; and continuous, remote (and thus low-resource)
monitoring of health conditions. Such services typically
combine data from multiple sources, which can be used
to inform patients, support self-management, and show
to healthcare practitioners a more complete picture.3
Management of health data is a rapidly growing
challenge worldwide. A global increase in smart health-
care, telecare and telehealth, means that there is a shift
toward digital health data on a significant scale, which
will eventually result in growing amounts of shared
data. Patients are far more mobile in a geographical
sense than ever before, and may access healthcare in
varied locations for numerous reasons.4 The UK’s
National Health Service (NHS) has been criticised in
recent years for continuing the use of ‘outdated’ tech-
nology, such as fax machines to transfer data, giving
rise to more calls for an update in the technology
employed within the system.5 NHS England’s Five
Year Forward View pledged in 2014 to implement
‘fully interoperable electronic health records so that
patients’ records are largely paperless. Patients will
have full access to these records, and be able to write
into them. They will retain the right to opt out of their
record being shared electronically’ and presented a
vision of a largely paperless NHS.6 To achieve this,
action is needed now, for sophisticated e-health solu-
tions to be developed, which can not only integrate
with current systems but also evolve alongside future
implementations.
Digital transformation is necessary to achieve serv-
ices exhibiting these qualities, including easier ways to
share data, and offering better consent models.7,8 The
UK, responding to a report by the National Data
Guardian,9 has introduced a national data opt-out
policy,10 which is implemented by compliance to the
NHS Digital DCB 3058.11 Managing and revoking
consent are also parts of the EU’s General Data
Protection Regulation, adopting good practice recom-
mendation into law.12,13 Patients need to be able to give
consent to data sharing or transfer of information
between healthcare organisations (e.g. General
Practitioner (GP) practices, pharmacies and specialist
hospital care) and clearly understand what data are
involved, as well as be able to revoke consent when
they wish to do so. Given the complexity of integrated
care service, informed consent can be difficult to main-
tain amongst all participating stakeholders, something
that is exacerbated by IT systems.5 The traditional,
paper-based approach to consent may hinder provision
of integrated services to patients.
Digital approaches to consent have increasingly
found their way into practice, offering advantages
such as accessibility to patient, enrichment with educa-
tional material, and electronic signature of the con-
sent.14–19 Transferring consent to health data sharing
amongst multiple systems is a considerable challenge,4
which does not easily allow the patient to maintain
clear knowledge of who has access to their health
data, how to amend these permissions when required,
or how to update their data across all of the different
systems. There are a number of barriers to efficient
data sharing within modern-day health IT systems
and how this impacts collaborative clinical decision
making, such as security and privacy concerns, lack
of trust relationships between healthcare entities, scal-
ability concerns and lack of interoperable data stand-
ards enforcement.20
The Dovetail Consent App is a mobile application
for patients to digitally consent to sharing their data
between services, using blockchain. This paper presents
an evaluation of patients’ attitudes towards the
deployed digital consent application as part of a pilot
for a phase 2 Small Business Research Initiative and
NHS England project. In the pilot, the Dovetail appli-
cation allowed patients with type 2 diabetes to offer
digital consent to having structured data relevant to
their condition, transferred from their GP to a diabetes
specific IT system.
Blockchain is a cryptographic, distributed peer-to-
peer ledger system which operates via a number of
nodes, all jointly responsible for the maintenance of a
database. The ledger is a virtual container of the data
of the transactions (e.g. financial transactions in
finance or consent requests in healthcare) that have
taken place within the system. The information that
constitutes the ledger is usually stored in multiple com-
puters, making it distributed. The data are contained
within ‘blocks’, each forming part of a chain. The
blocks are linked to each other using cryptography,
thus ensuring the integrity of the chain. Each time an
update is required to a block within the chain, nodes in
the network must collectively accept or decline the
change, and once this is agreed the network updates
accordingly.4 Blockchains can operate either a public
or a private system. In public systems (such as bitcoin),
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anyone can join and a large amount of computational
power is required across the network. In a private
system, all participants are known and require permis-
sion to join.21 Following the introduction and proof of
concept of blockchain technology in recent years, it has
become apparent that there is an opportunity to apply
the same technology to healthcare.20,22,23 Blockchain is
appreciated as a useful technology in healthcare.24 In
particular, blockchain’s smart contract (i.e. a transac-
tion between two parties, satisfying the requirements of
both, guaranteed by the IT infrastructure) can be used
as immutable authentication for digital consent.25–27
Using such an approach, a patient would be able to
consent to a transaction (e.g. sharing of their data
between two healthcare systems), with the details of
the transaction recorded in the chain. As the transac-
tion would be stored using cryptography, any change
would invalidate the chain. As the chain is distributed
to multiple computers, the system would be able to
retrieve the last valid chain (also containing the
patient’s approved transaction). Subsequent transac-
tions would be stacked in the chain without amending
the previous ones, offering traceability.
This paper presents a cross-sectional exploratory
study, evaluating the perception of patients towards
the use of dynamic digital consent technology. The
technology was implemented by the Dovetail digital
consent mobile application, deployed as part of a
broader pilot; offering a suite of self-management dig-
ital tools to patients with diabetes.
The Dovetail digital consent application
The Dovetail digital consent application is a mobile
application, for iOS and Android operating systems,
which enables users (patients) to consent to the sharing
of their data and subsequently triggers the transfer of
these data. The mobile application connects to the
Dovetail distributed ledger network where the consent
transaction is recorded. The Dovetail network,
through trusted integration, will notify local practice
systems that a patient has been informed of, and con-
sented to, a data exchange. A data exchange will take
place directly between the local GP practice and the
systems of the diabetes digital tools that participate in
the pilot. As a result, patients will be able to see their
data on diabetes specific applications, follow the prog-
ress of their care plan, add measurements, and request
expert advice. The Dovetail infrastructure does not
access any medical data, and only provides a descrip-
tion, and the provider and recipient of the data, as well
as the ID of the patient, which will be stored as a trans-
action in the chain.
The Dovetail consent application and Dovetail net-
work manage consent according to the dynamic
consent model.28 Consent is stored with reference to
the data being transferred and can be toggled indepen-
dently. The Dovetail network stores consent in private
channels between the sender, receiver, and Dovetail
(representing the patient). Consent to share additional
data can be added at later stages, and existing instances
of consent can be withdrawn or augmented by the user
(patient).
The Dovetail consent application provides a user
interface for patients to consent to their data being
transferred (Figure 1). Patients must first sign up to
the application, which includes confirming their identi-
ty by using the camera on their phone to photograph
their face, and a photographic identification document.
These two images are compared by the Dovetail appli-
cation to verify the identity of the patient. An identified
patient can use the application to give consent by
selecting a sender and a receiver of the data. After
the consent is created, the patient can view and
manage all their consents and the history of data trans-
fers associated with those consents.
Materials and methods
This is a cross-sectional exploratory mixed-methods
study. The goal of the study was to identify the
patients’ attitude towards the capability offered by
the Dovetail consent application. The study was con-
ducted using a mixed methods approach, in order to
yield both qualitative and quantitative data. Semi-
structured focus groups were carried out to gather qual-
itative feedback on the application and digital consent
technology. The focus groups covered previous experi-
ences and perception with giving/taking consent for
health data to be shared; attitudes towards and experi-
ence with technology, in general as well as for health-
care; perceived strengths and limitations of the app
capability in comparison with current methods; and
open discussion about any related issues. Discussions
were semi-structured, which allowed participants to
direct the conversation to a certain extent. This
allows rich, organic feedback to develop by allowing
the conversations to flow naturally (with some guid-
ance from the researcher to stay on-topic). This meth-
odology means that some topics of conversation were
not present in all focus groups, as they resulted from
discussions among participants or further questioning
on a specific point, rather than from the listed ques-
tions. The focus group discussions were audio
recorded, transcribed and analysed according to the
themes of the discussion.
All participants at the end of the focus groups com-
pleted questionnaires. This provided the opportunity to
explain the context, scope and terminology as well as
the capability of the digital consent application,
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offering confidence that participants have understood
the basic technological and capability tenets.
Questionnaire data were captured using a five step
Likert scale with 1 showing strong disagreement and
5 strong agreement (or strongly against and strongly in
favour respectively, depending on the phrasing of the
question). All questions were optional to participants,
to avoid potential noise in the data through forced
questions, and to offer a comfortable experience.
Quantitative analysis of the data was performed using
descriptive statistics. Where not all participants
answered a question, frequencies are expressed using
the valid percentage. The number of participants who
answered each question (n) out of the 23 patients and
13 staff is included in the results. The questionnaires
focused on three main areas: 1) identification of
patients’ perceptions towards existing consent
approaches, 2) identification of patients’ perceptions
towards the digital consent capability offered through
the Dovetail application, and 3) identification of
patients’ perception towards the overall effect of the
digital consent capability on the care they were receiv-
ing during the pilot.
One technology expert, one clinician and one inte-
grated care expert reviewed the questionnaires.
A Cronbach alpha test was performed to measure
internal consistency, in order to assess the reliability
of the Likert-based questionnaire.
The setting of the study was a GP practice in
England. The Dovetail digital consent application
was used to receive consent from the patients to have
their data shared between the practice and other dia-
betes self-management mobile applications.
Participants were invited to take part in the study
based on two criteria: being patients of the GP practice
in which the demonstrator was offered, and having a
diagnosis of either diabetes or pre-diabetes. Staff of the
GP practice with involvement in diabetes care and/or
patient record management were also invited. The staff
perspective allowed us to understand whether certain
attitudes were unique to patients, or could also be cor-
roborated by staff. Before the questionnaire and focus
group, the participants watched a video tutorial of how
the app works, as well as screenshots of the application
with further explanation. Following the video, ques-
tions were answered. The focus group preceded the
Figure 1. Screenshots of the Dovetail digital consent application. (a) Description of purpose for sharing the data, (b) overview of active
consents, (c) revocation of data sharing consent.
GP: General Practitioner
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questionnaire to ensure that all participants had under-
stood the purpose and operation of the application.
The study focused on patient perception of the
deployed application, and evaluation of the technical
implementation and its limitations was out of scope.
Use of blockchain as the underlying technology was
mentioned during the video and explained in layman
terms. The explanation did not go into technical
details, but was limited to highlighting: a) use of cryp-
tography in line with best practice in the finance indus-
try to guarantee integrity and immutability, b) storage
of information in the ledger containing the transaction
information and not any medical data.
The University of Warwick Biomedical & Scientific
Research Ethics Committee reviewed and approved the
study protocol with number REGO-2018-2277. All the
participants were given a participant leaflet with details
of the study and signed a consent form, according to
the approved protocol. Questionnaires were anony-
mous and the participants were given a time window
following the focus groups, during which they could
retract their questionnaire data using an unidentifiable
unique code.
Results
The sample consisted of a total of 36 participants, of
which 23 were patients and 13 were staff in the practice.
Figure 2 shows the demographics of the sample. The
staff sample covered all roles in the practice including
two GPs, two nurses, one healthcare assistant and eight
clerical staff.
Figure 3 illustrates the participants’ perceived skill
level in terms of using a smartphone device (this was an
open-ended question, which was further investigated
during the focus groups). Although smartphone skills
level could be considered as a potential barrier to par-
ticipants’ understanding the concepts of the study,
technology literacy was not a recruitment criterion.
10
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Figure 2. (a) Age of participants (n¼ 36), (b) gender of participants (n¼ 33).
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Figure 3. Smartphone skill level (n¼ 35).
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The evaluation focused on three themes: a) aware-
ness and understanding of existing consent practice, b)
evaluation of the dynamic patient-managed digital con-
sent Dovetail application, and c) evaluation of the tech-
nology against current practice. Albeit the majority of
patients were over 55 years of age, all of them declared
they were at least somewhat confident using a smart-
phone. An internal reliability Cronbach’s alpha test
was performed for the patient questions using the
Likert scale (a ¼ .856), indicating good consistency.
Awareness and understanding of existing
consent practice
The patients were generally not familiar with consent-
ing procedures, and most could not recall being asked
for their consent (Table 1). Some had experience of
operations and referrals, but still could not recall the
specific process of giving their consent for their health
data to be shared. FG3F1: ‘I don’t remember ever
being given something to sign’.
Two participants had recollections of complex con-
senting processes due to the management of long term
conditions, and could identify some of the inefficiencies
of the current processes (in large part due to having no
shared care pathway with their particular specialists).
FG1M3: ‘I think when I did it, it would be over five
years ago’; FG1M1: ‘we were given something to sign-
. . . it was on the iPad’. It was apparent that giving
consent to sharing data was not a significant event
for most of the patients (evidenced by the use of lan-
guage such as ‘I think . . .’, and the inability to recall
specific details of the process), despite the discussion
suggesting that some patients do hold strong opinions
on the subject of data sharing.
Healthcare professionals who were more involved in
this process were able to identify the point when
patients had given consent. Health data sharing
between systems or organisations was reported to
sometimes be difficult and even be a ‘nightmare’:
SFG3C8: ‘. . . a nightmare trying to get the shared care
sometimes, if we can’t get hold of the patient or the GP
practice, or the service they want to share it, and it does
delay the referral. Because we can’t actually action it
without getting that consent.’
This may affect the quality of care. SFG2N: ’ . . . I came
across this yesterday with a diabetic patient who’d been
for a foot check and has not shared care, so we cannot
see that diabetic patient’s foot review on the self-
management app’. Visibility between organisations
seems to be an issue that may result in additional
overheads.
SFG3C8: ‘If we weren’t aware . . .we find out, we’d still
continue to follow the process that we are, and asking
them and chasing it up. Because we wouldn’t know that
Table 1. Attitudes of patients towards awareness on consent.
Question f(1) f(2) f(3) f(4) f(5)
I have a good idea of who currently has access to
my health data (n¼ 23)
4 (17.4%) 3 (13%) 8 (34.8%) 3 (13%) 5 (21.7%)
If I wanted to change my preferences of who has
access to my health data, I would know how to
do this (n¼ 23)
8 (34.8%) 1 (4.3%) 8 (34.8%) 2 (8.7%) 4 (17.4%)
If I wanted to find out who has access to my health
data, I would know how to do this (n¼ 23)
8 (34.8%) 2 (8.7%) 6 (26.1%) 4 (17.4%) 3 (13%)
If I wanted to change my preferences of who has
access to my health data, I would find this easy
to do this (n¼ 23)
8 (34.8%) 1 (4.3%) 6 (26.1%) 4 (17.4%) 4 (17.4%)
If I wanted to find out who has access to my health
data, I would find this easy to do this (n¼ 23)
9 (39.1%) 2 (8.7%) 4 (17.4%) 4 (17.4%) 4 (17.4%)
I trust the current process of consenting to share
my health data (n¼ 23)
3 (39.1%) 1 (4.3%) 5 (21.7%) 5 (21.7%) 9 (39.1%)
I feel in control of who has access to my health
data (n¼ 23)
5 (21.7%) 2 (8.7%) 7 (30.4%) 2 (8.7%) 7 (30.4%)
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they’ve already consented, if it doesn’t link through
. . . to let us know somehow’.
It was also apparent that the staff had varied experi-
ence of consenting for health data sharing, due to dif-
ferences in their role responsibilities. For example,
nurses were less aware of consent practices mentioning:
SFG2N3: ‘I have no idea’, SFGN1: ‘Does reception;
I think it’s something that reception asks’, and
SFG2N3: ‘occasionally a screen pops up . . . and you
click a button if they consent to you looking at their
data . . . it’s a little bit grey. . .’. Whereas clerical staff
appeared more certain of the process: SFG3C8: ‘you
can ask them verbal consent over the telephone . . .we
don’t have to ask them every time’, which also is an
indication that the patients may lose touch of what they
have consented to after some time.
The attitudes of the patients towards data sharing
(in the context of receiving care) were generally relaxed,
with the proviso that the data sharing is to be with only
relevant entities within the NHS. Patients were
unaware who currently has access to their data, how
to find out, or how to withdraw their consent for their
data to be shared, which, however, did not prevent
patients from making assumptions about how their
data might be shared.
The issue of relevance was very important to
patients, and even those with a relaxed view on data
sharing were very clear that their data must only be:
FG1M1: ‘. . .shared relevantly, to the right department
or right people, not everyone’.
Evaluation of the dynamic patient-managed
digital consent capability offered by the
Dovetail application
A number of benefits to using the app were identified,
in comparison with paper-based consenting processes.
The primary benefits were that paper can be lost either
through human error or environmental issues such as
flooding or fire, and that paper is more difficult to con-
trol and track (Table 2). Electronic consent was viewed
as a potential solution to these problems and therefore
the app was viewed favourably in this respect; for
example: FG1M1: ‘the electronic is better because
there’s no paper involved and you can track it down,
and that’s how the systems – all over everywhere, is a
paperless system’, FG1F2: ‘paper gets lost doesn’t it?’;
FG6M2: ‘It wouldn’t go missing’; however, some par-
ticipants still favoured paper processes, as this was
what they were used to: FG1F1: ‘I like my paper . . . be-
cause it’s on hand, you can read it, you can pick it up’.
Another benefit identified was that the application
allows the patient to take more control, which previ-
ously had been something the participants did not feel
they had. Being able to access the app at any time
(FG1M2: ‘. . . you can do it from home’), from any-
where, was viewed as a positive and something that
would allow them to be more involved with their
health data. Furthermore, being able to view and
amend/update consents easily was regarded as a posi-
tive and as something which is not currently easy to do
(FG6M1: ‘It’s good, because you can see what
Table 2. Patients’ perceptions towards the Dovetail app.
Question f(1) f(2) f(3) f(4) f(5)
How easy do you think this app would be to use?
(n¼ 20)
1 (5%) 1 (5%) 5 (25%) 5 (25%) 8 (40%)
How suitable do you think this app is for managing
consent online? (n¼ 20)
1 (5%) 0 (0%) 8 (40%) 5 (25%) 6 (30%)
How likely would you be to try this app if it were
available to you? (n¼ 20)
1 (5%) 1 (5%) 1 (5%) 4 (20%) 13 (65%)
How well do you think this app provides solutions to
the drawbacks of paper based consent? (n¼ 20)
1 (5%) 0 (0%) 4 (20%) 6 (30%) 9 (45%)
How empowered would you feel using this app to
manage your own healthcare? (n¼ 21)
2 (9.5%) 1 (4.8%) 2 (9.5%) 6 (28.6%) 10 (47.6%)
How do you think this app would affect the number of
visits you would make to the GP? (1 ¼ greatly
increased, 2 ¼ increased, 3 ¼ no change,
4 ¼ reduced, 5 ¼ greatly reduced) (n¼ 20)
1 (4.3%) 0 (0%) 10 (50%) 2 (10%) 7 (35%)
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information is being shared, and if there’s anything on
there that you’re not happy about sharing, you can
withdraw your consent to share it’). The ability for
patients to be empowered through taking control of
their own data, will support wider patient self-
management and health empowerment goals.
Being able to see a visual confirmation that data
have been processed, being able to view current and
past consents and having control over data sharing at
any given time was seen as a benefit, for example:
FG6M1: ‘If you are the one who’s gone on the app to
give consent, then at least you know it’s been proc-
essed. There’s nothing worse than turning up at the
hospital appointment and they’ve no idea what
you’re talking about.’
It was generally agreed that the app could improve
feelings of control over one’s data.
FG3F1: ‘. . . you’ve got the option of stopping a con-
sent if you want to, so you’re still in control of what
happens so I think that’s very good . . .You always feel
like you’re not allowed to look, whereas with the app if
the information is there that you’re feeding to the app,
then you know what it is anyway, so you know, you’ve
got more knowledge.’
Evaluation of the technology against current
practice
Figure 4 shows the Likert frequencies of patient
responses to questions asked that compared their expe-
riences with the existing service, against the capability
of the digital consent application by Dovetail. From
front to back the questions asked of patients, focused
on: Q30) receiving better advice from healthcare
professionals (n¼ 23); Q31) controlling their medical
conditions (n¼ 21); Q32) improving the relationship
and interactions with healthcare professionals
(n¼ 23); Q33) provision of better access to specialists;
Q34) keeping track of who has access to the their data
(n¼ 22); Q35) removing data sharing when no longer
needing a specific service (n¼ 23); and Q36) updating
their health data across a number of services (n¼ 24).
Patients’ attitudes overwhelmingly shifted towards
strong agreement, with the capability improving a
number of aspects. It is noteworthy that there was a
significant shift from strong disagreement towards the
other extreme of the Likert scale.
A favourable opinion towards the application when
compared with existing service also prevailed in the
staff responses, although with more moderate shift in
attitude (Figure 5). From front to back the questions
asked focused on: S25) reduction of time spent on
administration (n¼ 13); S28) keeping track of who
has access to the practice’s patients’ health data
(n¼ 13); S33) supporting patients to manage their
own health data (n¼ 13); S35) supporting transparency
regarding health data sharing (n¼ 13); and S38) adher-
ing to data protection standards and requirements
(n¼ 13).
Discussion and conclusions
Overall, the capability of digital consent offered by the
Dovetail application was received favourably. Patients
saw a number of advantages of the application, partic-
ularly when compared with the existing process of
paper-based consent. The digital consent approach
was found to be easy to understand and use, and also
gave the perception of more control on the patients’
data. It is noteworthy that patients acknowledged
that the application offers a transparent and traceable
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Q30 Q31 Q32 Q33 Q34 Q35 Q36
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Figure 4. Perception of patients towards service improvement using digital consent (frequency of responses in valid percentages).
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process, which can be reviewed and amended at any
time, also highlighted in other uses of digital consent.19
There were benefits seen to a paperless system, includ-
ing time saving and increased control, as well as
reduced risk of data loss (though there were slight con-
cerns about hacking and electronic data). When discus-
sing current processes and consent to share health data,
it was evident that patients were not clear about how
things work or who currently has access to their health
data. Patients felt that they were not in control of their
own data, and were unaware of their options to be
more involved in their own data management. This
demonstrates a gap at the functionality level, which is
met by the Dovetail application.
In general, the patients were relaxed about sharing
their data, under the assumption that they would not
be shared outside the NHS, appreciating the value of
sharing data towards getting a better service. Although
not explicitly identified, a digital consent application
would further allow them to share the data with non-
NHS entities, as this would be declared in the applica-
tion. This is something that may not be apparent with
the current paper based approach, as being handled by
the GP practice. There is sometimes the mistaken
assumption that the sharing consent only refers to shar-
ing the data within an organisation, and not across
organisations. Staff agreed with the perception of the
patients, although they were more moderate towards
favouring digital consent. One major issue highlighted
was a potential added workload. This is probably due
to the fact that the pilot, in which the application was
used, took place in addition to their existing responsi-
bilities. Hence the pilot overall, may have actually con-
tributed to more workload. A different protocol would
need to conclusively investigate this, by comparing the
transformed, with the traditional service. Patients also
expressed that they would generally be willing to
submit anonymous data to researchers via the
application. The application has also managed to
offer clarity to an issue that both patients and staff
were not confident about. A technology assured con-
sent approach would transcend organisation changes,
and would offer the patients long-term continuous con-
trol over consent, which in other cases they may forget
about.
Participants in this study were recruited from one
local GP practice, therefore any generalisation should
be considered carefully. The pilot itself also experi-
enced technical difficulties due to network outages at
the pilot site, during the data collection period of the
study. Although the evaluation protocol was designed
based on the application mock-ups and instruction
videos, the technical difficulties may have introduced
biases in the responses of patients who anticipated
having used the application by that time.
Furthermore, the study evaluated the perception of
the patients towards the overall capability of the
Dovetail application, based on their experience
during the pilot, and not the merits of the technical
advantages of blockchain. Although the strengths of
the technology were presented, isolating the effect of
blockchain on the patients’ perception needs a more
targeted approach.
Finally, when compared with current practice, the
patients overwhelmingly responded favourably to the
digital consent capability, confirming the technology
benefit. Future work will incorporate evaluation with
broader demographic geographical diversity, as well as
larger patient sample. Additionally, evaluation of the
value to clinical researchers, as well as integrated care
delivery experts, has been identified as future work.
In conclusion, the patients received both the poten-
tial of the technology and the specific application pos-
itively. It was considered that it will allow patients to
manage their consent to having their data shared more
effectively. Staff identified that the digital consent
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Figure 5. Attitude of staff towards current practice and digital consent (frequency of responses in valid percentages).
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approach could help with delays in processing consent,
as well integrating services and organisations such as
GP practices and self-management applications.
Further research would need to confirm the results in
a wider geographical area, and strongly establish con-
fidence in the technology.
Contributorship: All authors contributed significantly to the
study and write-up of the article. Author #1 (GD): principal
investigator of the study. Contributed to the design, execu-
tion of the study and write-up of the article. Author #2 (JE):
contributed to the design, execution of the study and write-up
of the article. Author #3 (WN): contributed to the theoretical
background, and technical parts of the article. Author #4
(AE): lead of the SBRI project on development of the digital
consent service. Contributed to the logistics and the theoret-
ical background of the study. Author #5 (TR): contributed to
the design of the study, discussion and conclusions sections
and reviewed the article. Author #6 (TNA): contributed to
the design of the study, discussion and conclusions sections
and reviewed the article.
Conflict of interest: The author(s) declared the following
potential conflicts of interest with respect to the research,
authorship, and/or publication of this article: The authors’
organisations were part of the same publically funded
research and development project, led by Dovetail digital,
without any commercial interests between them. Dovetail
digital are developing the application into a commercial
service.
Ethical approval: The University of Warwick Biomedical &
Scientific Research Ethics Committee reviewed and approved
the study protocol with number REGO-2018-2277.
Funding: The author(s) disclosed receipt of the following
financial support for the research, authorship, and/or publi-
cation of this article: This work was supported by the Small
Business Research Initiative (SBRI) in healthcare, an
Academic Health Science Network (AHSN) led programme
for NHS England (grant number A-1296).
Guarantor: GD.
Peer review: Dr Gary Leeming, University of Manchester,
has reviewed the manuscript.
ORCID iDs: George Despotou https://orcid.org/0000-0003-
3437-6412
Theodoros N Arvanitis https://orcid.org/0000-0001-5473-
135X
References
1. World Health Organization, Regional Office for Europe.
Integrated care models: An overview. Working docu-
ment, http://www.euro.who.int/__data/assets/pdf_file/
0005/322475/Integrated-care-models-overview.pdf (2016,
accessed 1 May 2019).
2. Carewell project. Guidelines for implementing integrated
care in policy and practice; the journey to deploying scal-
able integrated healthcare services, http://carewell-proj
ect.eu/fileadmin/carewell/deliverables/d8.6_v2.0_care
well_guidelines_for_deployment_printable_version.pdf
(2017, accessed 1 May 2019)
3. Erturkmen GBL, Yuksel M, Sarigul B, et al. A collabo-
rative platform for management of chronic diseases via
guideline-driven individualized care plans. Comput Struct
Biotechnol J 2019; 17: 869–885.
4. Akarca D, Saleh K and Xiu P. Upgrading our digital
health infrastructures with blockchain-based records.
Cambridge Med J 2018; 1–4.
5. O’Connor Y, Rowan W, Lynch L, et al. Privacy by
design: Informed consent and internet of things for
smart health. Procedia Comput Sci 2017; 113: 653–658.
6. Maruthappu M, Sood HS and Keogh B. The NHS Five
Year Forward View: Transforming care. Br J Gen Pract
2014; 64: 635.
7. The King’s Fund. A digital NHS? An introduction to the
digital agenda and plans for implementation, https://
www.kingsfund.org.uk/sites/default/files/field/field_publi
cation_file/A_digital_NHS_Kings_Fund_Sep_2016.pdf
(2016, accessed 3 October 2019)
8. UK Department of Health and Social Care. The future of
healthcare: Our vision for digital, data and technology in
health and care. Policy Paper, https://www.gov.uk/gov
ernment/publications/the-future-of-healthcare-our-
vision-for-digital-data-and-technology-in-health-and-
care/the-future-of-healthcare-our-vision-for-digital-data-
and-technology-in-health-and-care (2018, accessed 3
October 2019).
9. UK National Data Guardian. Review of data security,
consent and opt-outs, https://www.gov.uk/government/
publications/review-of-data-security-consent-and-opt-
outs (2017, accessed 5 February 2020).
10. NHS Digital. National data opt-out operational policy
guidance document, https://digital.nhs.uk/services/nation
al-data-opt-out/operational-policy-guidance-document
(2019, accessed 5 February 2020).
11. NHS Digital, Data Coordination Board. DCB3058 com-
pliance with national data opt-outs standard, https://dig
ital.nhs.uk/data-and-information/information-standards/
information-standards-and-data-collections-including-
extractions/publications-and-notifications/standards-
and-collections/dcb3058-compliance-with-national-data-
opt-outs (2018, accessed 12 February 2020).
12. Official Journal of the European Union. Regulation (EU)
2016/679 of the European Parliament and of the Council
of 27 April 2016 on the protection of natural persons with
regard to the processing of personal data and on the free
movement of such data, and repealing Directive 95/46/
EC (General Data Protection Regulation), https://eur-
lex.europa.eu/legal-content/EN/TXT/HTML/?uri=
CELEX:32016R0679&from=EN (2016, accessed 1 May
2019).
10 DIGITAL HEALTH
13. Lea N. How will the general data protection
regulation affect healthcare? Acta Medica Portuguesa
2018; 31: 363.
14. Blake K, Hollbrock JT, Antal H, et al. Use of mobile
devices and the internet for multimedia informed consent
delivery and data entry in pediatric asthma trial: Study
design and rationale. Contemp Clin Trials 2015; 14:
05–118.
15. Gilber M, Bonnell A, Farrell J, et al. Click yes to consent:
Acceptability of incorporating informed consent into an
internet-based testing program for sexually transmitted
and blood-borne infections. Int J Med Inform 2017;
105:3 8–48.
16. Welch BM, Marshall E, Qanungo S, et al. Teleconsent: A
novel approach to obtain informed consent for research.
Contemp Clin Trials Commun 2016; 3: 4–79.
17. US Food and Drug Administration. Use of electronic
informed consent questions and answers; guidance for
institutional review boards, investigators, and sponsors,
https://www.fda.gov/media/116850/download (2016,
accessed 3 October 2019).
18. Budin-Ljosne I, Teare HJA, Kaye J, et al. Dynamic
consent: A potential solution to some of the challenges
of modern biomedical research. BMC Med Ethics 2017;
18: 4.
19. Teare HJA, Morrison M, Whitley EA, et al. Towards
‘Engagement 2.0’: Insights from a study of dynamic con-
sent with biobank participants. Digit Health 2015; 1:
1–13.
20. Zhang P, White J, Schmidt D, et al. FHIRChain:
Applying blockchain to securely and scalably share clin-
ical data. Comput Struct Biotechnol J 2018; 16: 267–278.
21. Pirtle C and Ehrenfeld J. Blockchain for healthcare:
The next generation of medical records? J Med Sys
2018; 42: 172.
22. Roehrs A, da Costa C and da Rosa Righi R. OmniPHR:
A distributed architecture model to integrate personal
health records. J Biomed Inform 2019; 71: 70–81.
23. Casino F, Dasaklis TK and Ptsakis C. A systematic
review of Blockchain-based applications: Current
status, classification and open issues. Telemat Inform
2019; 36: 55–81.
24. Gordon W and Catalini C. Blockchain technology for
healthcare: Facilitating the transition to patient-driven
interoperability. Comput Struct Biotechnol J 2018; 16:
224–230.
25. Drosatos G and Kaldoudi E. Blockchain applications in
the biomedical domain: A scoping review. Comput Struct
Biotechnol J 2019; 17: 29–240.
26. McGhin T, Choo KR, Liu CZ, et al. Blockchain in
healthcare applications: Research challenges and oppor-
tunities. J Network Comput Appl 2019; 135: 62–75.
27. Vazirani AA, O’Donoghue O, Brindley D, et al.
Implementing blockchains for efficient health care:
Systematic review. J Med Internet Res 2019; 21: e12439.
28. Kaye J, Whitley EA, Lund D, et al. Dynamic consent: A
patient interface for twenty-first century research net-
works. Eur J Hum Genet 2015; 23: 141–146.
Despotou et al. 11
